The T-SPOT Discovery SARS-CoV-2 kit has been developed to aid in the investigation of the T cell response to SARS-CoV-2 infection. The kit uses a modified ELISPOT assay where samples prepared from peripheral blood are stimulated in vitro by peptide pools from SARS-CoV-2. This re-stimulation allows SARS-CoV-2 specific T cells to be enumerated.
The kit builds on Oxford Immunotec’s experience with TB diagnosis and the assessment of immune response to CMV in transplant patients, to apply the Company’s established, proprietary T-SPOT technology to the fight against COVID-19. While serology is able to detect antibodies to SARS-CoV-2 in the blood of some individuals after infection, little is currently known about how this confers immunity to COVID-19. The T-SPOT technology goes further than simple serology by interrogating the immune system’s T cell response and will enable research into the measurement of the strength of that response to SARS-CoV-2. The strength of this response may be linked to protection from reinfection.
The T-SPOT technology is a proven technology, approved for clinical use to detect TB infection in over 60 countries including the US, China, Japan and Europe. With over 20 million clinical tests manufactured since release, the T-SPOT technology:
The T-SPOT Discovery SARS-CoV-2 kit is for Research Use Only. Not for use in diagnostic procedures.
Oxford Immunotec Global PLC is a global, high-growth diagnostics company. We bring energy and invention to a world in need of diagnostic truth. Our leading product, the T-SPOT.TB test, is used for diagnosing infection with tuberculosis, the world’s largest cause of death from infectious disease. The T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.
The Company is headquartered near Oxford, U.K. and in Marlborough, MA.